title: Use of response surface methodology in the formulation and optimization of bisoprolol fumarate matrix tablets for sustained drug release.
abstract: The aim of this investigation was to develop and optimize bisoprolol fumarate matrix tablets for sustained release application by response surface methodology based on 2(3) factorial design. The effects of the amounts of calcium alginate, HPMC K4M, and Carbopol 943 in bisoprolol fumarate matrix tablets on the properties of bisoprolol fumarate sustained release matrix tablets like drug release and hardness were analyzed and optimized. The observed responses were coincided well with the predicted values by the experimental design. The optimized bisoprolol fumarate matrix tablets showed prolonged sustained release of bisoprolol fumarate over 6 hours. These matrix tablets followed the first-order model with anomalous (non-Fickian) diffusion mechanism.
authors: Department of Pharmaceutics, Bengal College of Pharmaceutical Sciences and Research, Durgapur, West Bengal 713212, India.
authors: Jadupati
authors: J
authors: Malakar
authors: Amit Kumar
authors: AK
authors: Nayak
authors: Soumita
authors: S
authors: Goswami
references: J Control Release. 1998 Feb 12;51(2-3):313-25
references: 9685929
references: AAPS PharmSciTech. 2009;10(1):62-8
references: 19148762
references: Acta Pharm. 2007 Sep;57(3):269-85
references: 17878108
references: J Pharm Sci. 1961 Oct;50:874-5
references: 13907269
references: Int J Biol Macromol. 2011 Nov 1;49(4):784-93
references: 21816168
references: Yakugaku Zasshi. 2007 Aug;127(8):1281-90
references: 17666882
references: Acta Pharm. 2011 Mar;61(1):25-36
references: 21406341
references: Saudi Pharm J. 2009 Oct;17(4):283-8
references: 23960711
references: Int J Biol Macromol. 2012 Jan 1;50(1):138-47
references: 22020191
references: AAPS PharmSciTech. 2010 Jun;11(2):489-96
references: 20309652
references: Yakugaku Zasshi. 2010 Sep;130(9):1225-31
references: 20823680
references: Int J Biomed Sci. 2006 Dec;2(4):337-43
references: 23675002
references: J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1156-60
references: 6084774